Clinically accepted PDT
Treatment of solid tumors
Photodynamic therapy has received clinical acceptance for treatment of superficial tumours in the bladder, oesophagus and lung, and of non-oncological indications such as age-related macular degeneration and actinic keratosis.
PDT of tumours in the body (interstitial PDT) requires the transfer of light by optical fibres into the tumour tissue. It also requires predosimetry planning including treatment planning for optical fibre positioning and light dose calculation per optical fibre. Such treatment needs to be complemented with on-line monitoring of treatment-relevant parameters such as light dose, drug concentration and oxygen levels in real time.
One prarameter that has been identified in several studies to be essencial to a succesful outcome of the treatment is light control. As the geometry of the target tissue or location of nearby organs at risk is highly patient-specific as well as any treatment-induced changes of tissue composition may affect PDT dosimetry, the ability to steer the light is crucial.
SpectraCure’s sofisticated software IDOSE assures accurate positioning of the fibrers and due to a switching techique the fibrers switches between submitting light and exracting data during treatment in order to update the treatment parameters in realtime ensuring an accurant treatment for the patient.
One prarameter that has been identified in several studies to be essencial to a succesful outcome of the treatment is light control. As the geometry of the target tissue or location of nearby organs at risk is highly patient-specific as well as any treatment-induced changes of tissue composition may affect PDT dosimetry, the ability to steer the light is crucial.
SpectraCure’s sofisticated software IDOSE assures accurate positioning of the fibrers and due to a switching techique the fibrers switches between submitting light and exracting data during treatment in order to update the treatment parameters in realtime ensuring an accurant treatment for the patient.
Advancing cancer treatment with IDOSE®
